Anthracycline Chemotherapy and Cardiotoxicity
نویسندگان
چکیده
منابع مشابه
Anthracycline Cardiotoxicity
In this issue, Gupta et al describe a novel mechanism, mediated through alterations in the RNA-binding protein QKI (Quaking), responsible for anthracycline-mediated cardiotoxicity. Performing global transcriptional profiling in murine hearts exposed to doxorubicin, they identified 5 differentially expressed RNA-binding proteins: 4 of which were upregulated and 1 QKI which was downregulated. QKI...
متن کاملAnthracycline Cardiotoxicity
Anthracyclines remain an integral part of chemotherapy regimens in many adult and pediatric cancers but cause myocardial damage that may manifest as either subclinical decrements of left ventricular ejection function or overt cardiomyopathy. Anthracycline-related cardiotoxicity is doselimiting, and the risks of congestive heart failure increase with higher cumulative doses, particularly above 5...
متن کاملAnthracycline cardiotoxicity.
Anthracyclines remain an integral part of chemotherapy regimens in many adult and pediatric cancers but cause myocardial damage that may manifest as either subclinical decrements of left ventricular ejection function or overt cardiomyopathy. Anthracycline-related cardiotoxicity is doselimiting, and the risks of congestive heart failure increase with higher cumulative doses, particularly above 5...
متن کاملAnthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible heart failure. In this review, we discuss the pathogenesis and incidence of anthracycline-induced cardiotoxicity as well as methods to detect, prevent and ...
متن کاملAnthracycline-induced cardiotoxicity: risk assessment and management.
In the current issue of ONCOLOGY, Hershman and Shao provide a comprehensive review of anthracycline-induced cardiotoxicity (AIC). Risk factors for AIC include age (≤ 18 or ≥ 65 years) at time of treatment, increasing cumulative dose or dose intensity of anthracyclines, mediastinal radiation therapy (RT), and female gender.[1-4] The Surveillance, Epidemiology and End Results (SEER)-Medicare data...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cardiovascular Drugs and Therapy
سال: 2017
ISSN: 0920-3206,1573-7241
DOI: 10.1007/s10557-016-6711-0